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 Introduction 
 Cystic fi brosis (CF) is a lethal genetic disease in which dysfunction 
of the CF transmembrane conductance regulator (CFTR) chloride 
channel in bronchial epithelial cells prevents hydration of airway 
surface liquid (ASL) in the lung. Th ese thick secretions are a 
favorable environment for bacterial colonization, which incites 
chronic infl ammation and eventual respiratory failure from 
bronchiectasis. Th e natural history of CF is characterized by 
acute exacerbations during which patients experience new or 
worsened respiratory and constitutional symptoms referable 
to infection. 1 Although no consensus defi nition exists for CF 
pulmonary exacerbation (CFPE), 2 the phenomenon is associated 
with accelerated lung function decline and premature death. 3,4 
 At 3 months aft er intravenous antibiotics for CFPE, 25% of 
patients in a large cohort failed to regain their baseline percentage-
predicted forced expiratory volume in 1 second (FEV 1 %), a key 
spirometric endpoint in CF, as averaged over the 6 months before 
CFPE. Persistent infection by  Pseudomonas aeruginosa (PA) was 
an independent risk factor for this irreversible impairment. 5 
Growth within antibiotic-resistant biofi lm communities is one 
means by which PA persists in the CF lung. 6 Polarized bronchial 
epithelial cells that express dysfunctional CFTR release iron 
into ASL, which augments the overlying growth of PA biofi lms. 7 
Hence, abnormal iron handling by airway epithelial cells likely 
contributes to PA lung infection in CF. 
 Clinical studies support the premise that iron homeostasis is 
uniquely aberrant in this disease. Th e iron content of CF sputum 
is approximately 2.5–5.5 times higher than sputum from patients 
with chronic obstructive pulmonary disease (COPD) and about 
3.4–4.2 times higher than sputum from normal controls. 8–10 Reid 
et al. 11 reported a signifi cant direct relationship between sputum 
iron and quantitative culture of PA, suggesting that its growth 
is related to iron availability. Th ree investigations 9–11 with a total 
of 34 subjects have revealed that sputum iron content does not 
change aft er CFPE therapy, but none of them addressed iron-
related hematologic parameters. 
 Excess lung iron in CF presumably originates from host reserves 
despite complex regulatory mechanisms governing its uptake, 
utilization, and storage. Iron is necessary for oxygen transport by 
hemoglobin, mitochondrial energetics, and modulation of gene 
transcription. 12 Its absorption from dietary sources by duodenal 
enterocytes is markedly reduced during states of infl ammation 
and systemic iron overload by the activity of hepcidin-25. 13 Th is 
polypeptide hormone of hepatic origin triggers the degradation 
of the iron-exporting protein ferroportin in mononuclear cells 
and enterocytes resulting in iron sequestration and attenuated 
uptake, respectively. 14,15 By these mechanisms, hepcidin-25 lowers 
blood iron, a condition called hypoferremia. Interleukin-6 (IL-6) 
potently stimulates hepcidin-25 production 16 thereby linking iron 
regulatory pathways to the infl ammatory milieu. Th e hepcidin-
IL-6 axis has heretofore not been investigated in CF. 
 Th e main goal of this study was to characterize how CFPE 
treatment infl uences iron handling in the circulatory and airway 
compartments given a paucity of data from concurrent assessment. 
Based on the available literature and our fi ndings, we hypothesized 
that CFPE treatment would be associated with higher iron, and 
lower hepcidin-25 and IL-6 serum concentrations. Moreover, 
we postulated that sputum iron content would fall in response 
to treatment. 
 Methods 
 Defi nitions 
 CFPE was defi ned by new or acutely worsened sinopulmonary 
and constitutional signs and symptoms that included the 
following: increased cough frequency, increased daily sputum 
expectoration, wheezing, dyspnea, fevers, chills, sweating, 
anorexia, and weight loss. 17 An attending pulmonologist with 
longitudinal experience in caring for a given subject determined 
whether CFPE was apparent. Early CFPE was a point <24 hours 
aft er CFPE determination, and late CFPE was a point <24 hours 
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 Abstract 
 Background: Hypoferremia is a marker of disease severity in cystic fi brosis (CF). The effect of systemic antibiotics on iron homeostasis 
during CF pulmonary exacerbation (CFPE) is unknown. Our central hypotheses were that, by the completion of treatment, serum iron 
would increase, serum concentrations of interleukin-6 (IL-6) and hepcidin-25, two mediators of hypoferremia, would decrease, and 
sputum iron would decrease. 
 Methods: Blood and sputum samples were collected from 12 subjects with moderate-to-severe CF (median percentage-predicted 
forced expiratory volume in 1 second (FEV 1 %) = 29%; median weight = 56 kg) within 24 hours of starting and completing a course 
of systemic antibiotics. 
 Results: After treatment, subjects showed median FEV 1 % and body weight improvements of 4.5% and 2.0 kg, respectively ( p < 0.05). 
Median serum iron rose by 2.4 µmol/L ( p < 0.05), but 75% of patients remained hypoferremic. Median serum IL-6 and hepcidin-25 
levels fell by 12.1 pg/mL and 37.5 ng/mL, respectively ( p < 0.05). Median serum erythropoietin (EPO) and hemoglobin levels were 
unaffected by treatment. We observed a trend toward lower sputum iron content after treatment. 
 Conclusions: Hypoferremia is a salient characteristic of CFPE that improves with waning infl ammation. Despite antibiotic treatment, 
many patients remain hypoferremic and anemic because of ineffective erythropoiesis. Clin Trans Sci 2012; Volume 5: 368–373
 Keywords:  iron ,  hepcidin ,  cystic fi brosis ,  interleukin-6 ,  exacerbation 
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before fi nishing treatment. No subject received more than two 
scheduled doses of systemic antibiotics before drawing blood at 
the early CFPE time point. Th e duration of hospitalization was 
not specifi ed  a priori and was infl uenced by how long the subject 
wanted to remain in the hospital and the attending physician’s 
appraisal of clinical progress. We defi ned hypoferremia according 
to other CF studies 17–19 as a serum iron 12 μmol/L, a threshold 
below which erythropoiesis becomes iron limited. 20 A hemoglobin 
level <13.7 g/dL, the lower limit of the reference range for our 
laboratory, established a diagnosis of anemia. 
 Enrollment 
 Blood and sputum samples were obtained from 12 adults with CF 
during early and late CFPE aft er provision of informed consent. 
Th e Committee for the Protection of Human Subjects (CPHS) 
at Dartmouth College approved the study protocol. Age ≥18 
years and a history of PA airway colonization were inclusion 
criteria. Subjects were not eligible to participate if they were 
taking supplemental iron and if inclusion criteria were not 
satisfi ed. All subjects were treated with dual systemic antibiotics 
against PA based on susceptibility testing from the most recent 
sputum culture. No subject received iron supplementation or 
transfusion of packed red blood cells. Two subjects were using 
systemic corticosteroids or nonsteroidal antiinfl ammatory drugs 
before hospital admission, and these were continued without dose 
escalation. Sputum samples were spontaneously expectorated 
(i.e., not induced by inhalation of hypertonic saline) and were 
excluded from trace element analysis if any blood was visible. 
Routine chest physiotherapy and consultation with a nutritionist 
and a diabetes nurse specialist (if applicable) were off ered to all 
subjects. Th e volume of blood drawn at each time point (i.e., early 
and late CFPE) was approximately 25 mL. 
 Measurement of complete blood counts and serum iron 
 Complete blood counts were done using a Sysmex XE-2100 
autoanalyzer (Sysmex America, Inc., Mundelein, IL, USA). Serum 
iron was determined using a COBAS c311 autoanalyzer (Roche 
Diagnostics USA, Indianapolis, IN, USA). 
 Measurement of serum hepcidin-25 
 Serum hepcidin-25, the physiologically active polypeptide 
hormone of iron regulation, was quantifi ed according to an 
established protocol 21 at Intrinsic LifeSciences, LLC (LaJolla, 
CA, USA). Briefl y, the technique is a competitive enzyme-
linked immunosorbant assay (C-ELISA) using biotinylation as 
a detection method. Samples were analyzed in duplicate, and 
mean values were used in subsequent calculations. Th e lower 
limit of detection was 5 ng/mL. 
 Measurement of serum erythropoietin 
 Serum erythropoietin (EPO) was measured using a commercially 
available double-sandwich ELISA (Quantikine® IVD®, R&D 
Systems, Inc., Minneapolis, MN, USA), according to the 
manufacturer’s instructions. Samples were analyzed singly. Th e 
lower limit of detection was 2.5 mU/mL. 
 Measurement of serum IL-6 
 Serum IL-6 was quantified using Bio-Plex human cytokine 
multiplex kits (Bio-Rad Inc., Hercules, CA, USA), according 
to the manufacturer’s instructions. Samples were analyzed in 
triplicate, and mean values were used in subsequent calculations. 
For samples in which the concentration of IL-6 was undetectable, 
the lower limit of detection (1.9 pg/mL) was used in statistical 
analyses. 
 Measurement of sputum iron 
 Whole sputum plugs were weighed and digested with a standard 
volume of nitric acid. Total inorganic iron in each aliquot was 
quantifi ed by inductively coupled plasma–mass spectroscopy 
(ICP–MS) 17 and is expressed as nanograms of iron per milligram 
of sputum. 
 Data analysis 
 Data are presented as medians and ranges unless otherwise noted. 
Biochemical parameters for each patient during early and late 
CFPE were compared using the Wilcoxon matched-pairs signed-
rank test. Th e strength of association between nominal variables 
is given by Spearman rank correlation ( ρ ). A two-tailed  p -value 
of <0.05 was considered statistical signifi cant. GraphPad Prism® 
5.0 (GraphPad Soft ware, San Diego, CA, USA) was used for all 
analyses. 
 Results 
 Patients and treatment 
 Clinical attributes of the cohort at the time of CFPE 
determination are listed in  Table 1 . Th e median age of the cohort 
was 32 years. In general, patients had severe pulmonary function 
impairment, nutritional insuffi  ciency, CF-related diabetes, 
hypoferremia, and mild anemia, a chronic illness phenotype 
that we described in a larger cross-sectional study. 17 Fift y-eight 
percent of patients possessed two F508-CFTR alleles, which 
is similar to the frequency of homozygosity for this mutation 
in Caucasians. 22 Patients received antibiotics for a median of 
12 days (range: 5–19), which is congruent with pervasive 
practice patterns. 23 
 CFPE Treatment is associated with weight gain and improved 
lung function 
 We compared clinical parameters for subjects in early versus 
late CFPE. In all cases, early CFPE was a point <24 hours aft er 
CFPE determination, and late CFPE was a point <24 hours before 
fi nishing treatment. Median increases in body weight and FEV 1 % 
were 2.0 kg and 4.5%, respectively ( p < 0.01 for late CFPE vs. 
early CFPE;  Figures 1A and B ). Body weight and FEV 1 % were 
N = 12
Age (years) 32 (18–53)a
Gender (M/F) 9/3
FEV1 (% predicted) 29 (21–48)
a
Body weight (kg) 55.5 (40.2–75.1)a
F508-CFTR homozygote 7 (58)b
CF-related diabetes 11 (92)b
Serum iron (µmol/L) 4.8 (1.6–16.1)a
Hemoglobin (g/dL) 12.9 (10.1–15.2)a
CFPE = CF pulmonary exacerbation. Data are presented as median and (ranges)a or 
number of subjects and (percentages)b.
 Table 1.  Clinical characteristics of subjects at early CFPE. 
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significantly correlated at early 
CFPE ( ρ = 0.76,  p < 0.01) but 
not at late CFPE. FEV 1 % directly 
correlated with serum iron at 
early CFPE ( ρ = 0.58) and late 
CFPE ( ρ = 0.65;  p < 0.05 for both 
correlations). 
 CFPE treatment is associated 
with higher serum and lower 
sputum iron concentrations 
 Our previous work indicated a 
link between high serum iron, 
low sputum iron, and increased 
FEV 1 %. Therefore, we assessed 
these parameters in CFPE subjects 
before and after treatment with 
IV antibiotics. According to our 
defi nition of hypoferremia (serum 
iron 12 μmol/L), 10 of 12 subjects 
(83%) were hypoferremic at early 
CFPE. Median serum iron rose by 
2.42 μmol/L (13.5 mg/dL) by the 
end of therapy ( Figure 2A ). All 
but one of the subjects who were 
hypoferremic at early CFPE had 
serum iron readings <12 μmol/L 
at late CFPE and thus, remained 
iron-defi cient. Only 9 of 12 subjects 
(75%) who furnished sputum 
samples at early CFPE were able 
to provide follow-up samples at 
late CFPE, which is not unusual 
for patients after completing a 
course of intravenous antibiotics. 
Among these subjects, median 
sputum iron fell by 0.92 ng/mg, 
a value that approached but did 
not attain significance at a 95% 
CI ( p = 0.055;  Figure 2B ). Serum 
and sputum iron did not correlate 
signifi cantly at early or late CFPE, 
which is a similar fi nding to our 
cross-sectional analysis of these 
parameters. 17 
 CFPE treatment is associated 
with lower serum hepcidin-25 
and IL-6 levels 
 We next quantified known 
mediators of iron homeostasis 
to explore possible mechanisms 
by which serum iron increased 
posttreatment. Median serum IL-6 
fell by 12.1 pg/mL ( p < 0.05 for late 
CFPE vs. early CFPE;  Figure 3A ). 
Median serum hepcidin-25 was 
37.5 ng/mL lower at late CFPE ( p < 0.01) ( Figure 3B ). Serum 
iron did not correlate with hepcidin-25 at either time point during 
CFPE; however, serum IL-6 was indirectly correlated with serum 
iron at late CFPE ( ρ = –0.66,  p < 0.05). 
 CFPE treatment does not infl uence hemoglobin and serum 
erythropoietin 
 Given the observed changes in serum iron and regulators of 
iron homeostasis posttreatment, we next assessed the impact of 
 Figure 1.  Changes in body weight and FEV1% during treatment. Median values are denoted by the line within each shaded box. 
The upper and lower boundaries of the shaded box refl ect the interquartile range of data. Whiskers signify minimum and maxi-
mum values.  ** p < 0.01 for comparison by Wilcoxon matched-pairs signed-rank test. CFPE = CF pulmonary exacerbation. 
 Figure 2.  Changes in serum iron and sputum iron during treatment. Median values are denoted by the line within each 
shaded box. The upper and lower boundaries of the shaded box refl ect the interquartile range of data. Whiskers signify mini-
mum and maximum values.  * p < 0.05 for comparison by Wilcoxon matched-pairs signed rank test. CFPE = CF pulmonary 
exacerbation. 
 Figure 3.  Changes in serum IL-6 and hepcidin-25 during treatment. IL-6 = interleukin-6. Median values are denoted by the line 
within each shaded box. The upper and lower boundaries of the shaded box refl ect the interquartile range of data. Whiskers 
signify minimum and maximum values.  * p < 0.05,  ** p < 0.01 for comparison by Wilcoxon matched-pairs signed-rank test. 
CFPE = CF pulmonary exacerbation. Note: logarithmic scale of ordinate. 
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these changes on anemia. During the treatment interval, median 
hemoglobin increased by only 0.1 gm/dL ( Figure 4A ). Th e median 
serum EPO concentration rose by 2.1 mU/mL ( Figure 4B ). 
Neither diff erence was statistically signifi cant. Serum iron directly 
correlated with hemoglobin at early CFPE ( ρ = 0.87,  p < 0.01) and 
late ( ρ = 0.58,  p < 0.05) CFPE. Sputum iron did not correlate with 
hemoglobin. Th us, the observed changes in iron and mediators of 
iron homeostasis had no discernable eff ects on anemia. 
 Discussion 
 Th is prospective study was done to characterize iron homeostasis 
within the context of CFPE, periods of acutely compromised health 
that frequently occur in this disease and adversely aff ect prognosis. 
In a small cohort of adults treated with antibiotics and supportive 
care, we found that improved lung function and weight gain were 
associated with higher serum iron and lower circulating levels of 
mediators known to restrict iron bioavailability. Most of the subjects 
remained hypoferremic and mildly anemic despite statistically 
signifi cant increases in serum iron. We observed a trend toward 
lower sputum iron content aft er treatment in 9 of the 12 subjects 
for whom samples were available from early and late CFPE. 
 Studies focusing on CFPE treatment responses are 
methodologically diverse; however, those in which intravenous 
antibiotics are used and changes in FEV 1 % and body weight are 
reported, as in our study, demonstrate that these parameters 
improve modestly and commensurately. 24,25 Therefore, our 
subjects’ treatment responses were not unusual. According to 
the 2010 CF Foundation patient registry, the median duration 
of intravenous antibiotic therapy for adults with CFPE in the 
United States was 14.7 days, with a range of 7.8–23.3 days. 26 
Th e median in our study was 12 days with a range of 5–19 days, 
slightly shorter than nationwide medical practice. Treatment 
duration certainly could impact the extent to which biomarkers 
of iron homeostasis vary. Nonetheless, in our study, the subject 
with the shortest treatment interval (5 days) still experienced a 
0.5 kg increase in body weight, a 6% improvement in FEV 1 %, a 
1.79 μmol/L increase in serum iron, and reductions in serum IL-6 
and hepcidin-25 of 2 pg/mL and 104.9 ng/mL, respectively. Th ese 
trends are similar to those observed among subjects treated for 
longer periods. Discerning how the length of therapy infl uences 
iron homeostasis during CFPE will require a study in which this 
parameter is controlled. 
 A signifi cant limitation of our work is the inability to distinguish 
which interventions in a multifaceted regimen contributed 
more or less dramatically to the 
endpoints of better lung function 
and weight gain. Subjects not 
only received dual systemic 
antibiotic coverage for PA but also 
nutritional supplementation and 
daily airway clearance sessions to 
mitigate secretions. Th e majority 
of the cohort was diabetic, and as 
such, received insulin for glycemic 
control. Because these therapies 
represent standards-of-care in CF, 
it will be diffi  cult to evaluate how a 
specifi c modality infl uences these 
metrics. 2,27 
 To our knowledge, this is 
the first investigation to show 
that serum iron increases in response to CFPE therapy and the 
fi rst to off er insights into possible mechanisms for this fi nding 
by examining trends in hepcidin-25 and IL-6. Cross-sectional 
analyses 18,28 of CF patients with varying disease severity report 
that hypoferremia has a prevalence of 62–74%. Applying a similar 
defi nition of iron defi ciency to two adult CF cohorts, we found 
that subjects who recently experienced clinical deterioration had 
higher IL-6 and lower iron levels in plasma than those in good 
health, 17 which led us to suspect that IL-6 mediates hypoferremia 
in this disease. Nixon et al. 29 found that mean serum IL-6 in 12 
patients with CFPE fell by 5.12 pg/mL ( p < 0.01) aft er antibiotics, 
but they did not investigate how reductions in this cytokine related 
to changes in serum iron, hepcidin-25, and hemoglobin. Th erefore, 
the median reduction in serum IL-6 that we observed (12.1 pg/mL) 
not only supports their observation but also highlights its clinical 
relevance by demonstrating how IL-6 relates to other biomarkers 
of iron homeostasis in CF. 
 We can fi nd no published data supporting the contention that 
CFPE onset is heralded by increases in sputum iron. However, data 
from 34 subjects in 3 studies 9–11 suggest that sputum iron does not 
change signifi cantly aft er antibiotics. Using a colorimetric assay to 
quantify total iron in denatured sputum samples from 14 patients, 
Reid et al. 9 found that median iron content was not diff erent 
between the outset (47 μmol/L) and the end (33 μmol/L) of therapy 
( p = 0.1). Th e median duration of antibiotic administration in this 
study 9 was 12 days, which compares favorably with our median 
treatment interval (12 days). In six additional patients, Reid 
et al. 11 demonstrated that sputum iron was unaltered aft er a median 
of 8 antibiotic days (35.3 μmol/L vs. 35.6 μmol/L,  p > 0.05). For 
a cohort of 14 patients, Gray et al. 10 used ICP-MS to show that 
sputum iron, unlike sputum zinc, did not fall signifi cantly aft er 
CFPE therapy, although they do not provide the sputum iron data 
and do not comment on treatment modalities or their duration. 
Herein, we identifi ed a trend toward lower sputum iron at the end 
of CFPE treatment in 9 of 12 subjects. A lack of paired samples 
for iron quantifi cation in three instances is clearly a source of 
type II error that limits our ability to ascertain whether CFPE 
treatment reduces sputum iron. However, our observation that 
CFPE treatment does not change this parameter could also be 
consistent with the fi ndings of the aforementioned authors. 9–11 
Future investigations of sputum iron trends in CF should ensure 
uniformity of analytical techniques and treatment length and be 
adequately powered to detect a prespecifi ed change in response 
to a specifi c intervention. 
 Figure 4.  Changes in hemoglobin and serum erythropoietin during treatment. Median values are denoted by the line within 
each shaded box. The upper and lower boundaries of the shaded box refl ect the interquartile range of data. Whiskers signify 
minimum and maximum values. CFPE = CF pulmonary exacerbation. EPO = erythropoietin. 
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 ICP–MS, the technique employed herein to measure total 
iron in each sputum aliquot, does not provide information about 
how the metal is distributed within the sample. Th e amount of 
iron in CF sputum could be proportional to the quantitative PA 
burden, as Reid et al. 11 advance, but it could also refl ect iron 
bound to human airway proteins like ferritin and lactoferrin 
and to bacterial iron-scavenging molecules called siderophores. 30 
Regardless of the metal’s distribution, lower total sputum iron 
following CFPE treatment is theoretically advantageous because 
PA biofi lm growth is augmented by iron. 7 
 We provide evidence for ineff ective erythropoiesis during 
CFPE, as hemoglobin levels were unaltered by treatment. Our data 
suggest two possible explanations for persistent anemia: serum 
iron was insuffi  cient to support erythropoiesis and/or serum EPO 
did not adequately stimulate the growth and diff erentiation of 
erythrocyte precursors in the face of greater iron bioavailability. 
Th e former explanation is most likely given that erythropoiesis is 
impaired at serum iron levels 12 μmol/L, 20 and serum iron did 
not exceed this value in 75% of patients aft er treatment. 
 Our study design does not account for the potential eff ect 
of routine phlebotomy on lowering hemoglobin. Serial blood 
sampling for diagnostic tests can cause “iatrogenic” or “nosocomial” 
anemia during hospital admission, mainly because collected 
blood volumes oft en far exceed the minimum amount necessary 
for satisfactory assay performance. 31 For several reasons, this 
bloodletting phenomenon is unlikely to have contributed to our 
fi nding that median hemoglobin concentration did not increase 
by late CFPE. First, we obtained roughly 25 mL of blood at each 
of the two CFPE time points. A retrospective analysis of factors 
that signifi cantly contributed to changes in hemoglobin values 
among general medical inpatients found that for every 50 mL of 
blood removed by phlebotomy, mean hemoglobin concentration 
would be expected to fall by 0.35 g/dL (95% CI, 0.24–0.46). 32 
Median hemoglobin at late CFPE was actually a bit higher than 
at early CFPE ( Figure 4A ). Second, our subjects did not represent 
a hospitalized population at risk for large-volume phlebotomy. 
Wisser et al. 33 reported that iatrogenic blood loss of >200 mL is 
almost exclusively observed in patients with long-term mechanical 
ventilation, coagulation disorders, and repeated surgery. Th ese 
features do not apply to the CF subjects in our study. 
 In conclusion, we found that recovery from CFPE is 
associated with higher serum iron levels, weight gain, and better 
lung function. Th e waning infl ammatory milieu, as refl ected by 
lower posttreatment serum hepcidin-25 and IL-6 concentrations, 
likely underlies the signifi cant improvement in hypoferremia. 
Despite an increase in circulating iron reserves aft er treatment, 
a signifi cant erythropoietic response was not identifi ed. Our 
fi nding of no statistically signifi cant reduction in sputum iron 
after antibiotics is consistent with several studies. 9–11 These 
fi ndings raise the possibility that biochemical measures of iron 
homeostasis, particularly those from blood samples, could be used 
as surrogate endpoints in the design of CF treatment trials. 
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